Washington, DC - Antiretroviral therapy (ART) is usually very effective at suppressing HIV in the body, allowing a person’s immune system to recover by preventing the virus from destroying CD4+ T cells (link is external). Scientists have now identified a rare, paradoxical response to ART known as extreme immune decline, or EXID. Five individuals evaluated at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, experienced a significant decline in CD4+ T cell levels despite suppression of HIV below detectable levels for more than three years, according to a report published online today in JCI Insight.

Washington, DC - Two proteins that bind to stress hormones work together to maintain a healthy heart in mice, according to scientists at the National Institutes of Health and their collaborators. These proteins, stress hormone receptors known as the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR), act in concert to help support heart health. When the signaling between the two receptors is out of balance, the mice have heart disease.

Washington, DC - As we continue to address the troubling epidemic of youth e-cigarette use, we’ve committed to employing a number of tools as part of our Youth Tobacco Prevention Plan to ensure no tobacco products are being marketed to, sold to, or used by kids. We’ve taken a series of escalating enforcement actions. We’ve launched public education campaigns to warn youth about the dangers of e-cigarette and other tobacco product use. And most recently, we advanced new policies aimed at preventing youth access to, and appeal of, flavored tobacco products, including e-cigarettes and cigars.

Washington, DC - The U.S. Department of Agriculture (USDA) in coordination with the U.S. Department of Health and Human Services (HHS), invites the public to register to attend the first meeting of the 2020 Dietary Guidelines Advisory Committee. The meeting will be held at USDA headquarters in the Jefferson Auditorium on March 28th and 29th. Registration for in-person attendance begins today and closes at 5:00 p.m. March 26, 2019.

Washington, DC - The U.S. Food and Drug Administration approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD.

Washington, DC - Presidential Message on National Colorectal Cancer Awareness Month: